Latest from Moffitt

Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.
Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses the rationale and design of a phase II study of TAS-102 (trifluridine/tipiracil; Lonsurf) in combination with ramucirumab (Cyramza) in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma (NCT03686488).
Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.
Bijal D. Shah, MD, oncologist/hematologist, Moffitt Cancer Center, discusses ongoing trials in the field of mantle cell lymphoma (MCL).
Bijal D. Shah, MD, associate member, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses challenges with developing mantle cell lymphoma clinical trials.
Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in the treatment of mantle cell lymphoma.
Richard Kim, MD, assistant professor of oncology, University of South Florida College of Medicine, medical oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center, discusses the role of frontline immunotherapy in patients with advanced hepatocellular carcinoma.
Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.
Publication Bottom Border
Border Publication
x